Results 231 to 240 of about 42,414 (275)

Monovalent Type 1 Oral Poliovirus Vaccine in Newborns

New England Journal of Medicine, 2008
In 1988, the World Health Assembly resolved to eradicate poliomyelitis. Although substantial progress toward this goal has been made, eradication remains elusive. In 2004, the World Health Organization called for the development of a potentially more immunogenic monovalent type 1 oral poliovirus vaccine.We conducted a trial in Egypt to compare the ...
N, El-Sayed, Y, El-Gamal, AA, Abbassy, I, Seoud, M, Salama, A, Kandeel, E, Hossny, A, Shawky, HA, Hussein, Pallansch, MA, van der Avoort, HGAMrivm, AH, Burton, M, Sreevatsava, P, Malankar, MJ, Wahdan, Sutter, RW   +15 more
openaire   +4 more sources

The Humoral Immune Response to Type 1 Oral Poliovirus Vaccine in Children Previously Immunized With Enhanced Potency Inactivated Poliovirus Vaccine or Live Oral Poliovirus Vaccine

Archives of Pediatrics & Adolescent Medicine, 1990
Sixty-one children who had previously received three doses of enhanced potency inactivated poliovirus vaccine (epIPV) at 2, 4, and 18 months of age and 56 children who had previously received oral poliovirus vaccine (OPV) according to the same schedule were challenged with a single dose of monovalent, type 1 oral poliovirus vaccine (OPV1) between 19 ...
Mary Lou Thorns, A. Marshall McBean, Roger H. Bernier, Paul Albrecht, Lynda Nerhood, Ida M. Onorato, John F. Modlin   +6 more
openaire   +3 more sources

The Thermostability of Vaccines: Technologies for Improving the Thermostability of the Oral Poliovirus Vaccine

International Journal of Technology Assessment in Health Care, 1994
AbstractTechnologies that promise to enhance the stability of vaccines are likely to be determined by the product-specific physical structure and biological functions of the specific vaccine immunogens. Research may define the extent to which the stability of oral poliovirus vaccine may be improved by the addition of certain antiviral components that ...
Stanley M. Lemon, Julie B. Milstien
openaire   +3 more sources

Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial.

Lancet. Infectious Diseases (Print), 2023
A. Wilkinson, K. Zaman, M. Hoque, C. Estivariz, C. Burns, Jennifer L. Konopka-Anstadt, Bernardo A. Mainou, Stephanie D. Kovacs, Qian An, Jacquelyn S. Lickness, Mohammad Yunus, C. Snider, Yiting Zhang, Elizabeth Coffee, T. Abid, S. Wassilak, M. Pallansch, M. Oberste, J. Vertefeuille, A. Anand   +19 more
semanticscholar   +1 more source

Some Problems of Administering Oral Poliovirus Vaccine

Clinical Infectious Diseases, 1984
Ten years of mass vaccination with oral poliovirus vaccine (OPV) have brought poliomyelitis under effective control in most parts of China and have greatly reduced its incidence. Outbreaks of poliomyelitis and poliomyelitis-like disease are occasionally reported in areas far from the big cities, however, and these outbreaks influence the total ...
openaire   +3 more sources

Oral, Live Poliovirus Vaccine for Elimination of Poliomyelitis

Archives of Internal Medicine, 1960
After many years of experimentation and small-scale studies with various attenuated strains of poliovirus, followed by trials on successively larger numbers of persons with the strains that were finally selected, millions of human beings received oral poliovirus vaccines in 1958 and 1959 under a great variety of conditions in many different parts of ...
openaire   +3 more sources

Poliomyelitis Prevention: Recommendations for Use of Inactivated Poliovirus Vaccine and Live Oral Poliovirus Vaccine

Pediatrics, 1997
A change in the recommendations for routine immunization of children is indicated because of the reduced risk of exposure to wild-type polio viruses and the continued occurrence of vaccine-associated paralytic poliomyelitis after oral polio vaccine (OPV). All children should receive four doses of vaccine before the child enters school.
Richard F. Jacobs, Michael A. Gerber, Noni E MacDonald, Neal A. Halsey, Steve Kohl, N. R. Rabinovich, Melvin I. Marks, M. C. Hardegree, Dennis Murray, J. C. Overall, P. J. Chesney, D. S. Gromisch, Larry K. Pickering, Richard J. Whitley, Georges Peter, Robert F. Breiman, Walter A. Orenstein, Caroline B. Hall, Ram Yogev, S. M. Marcy, B. Schwartz   +20 more
openaire   +2 more sources

Current issues in evaluating the efficacy of oral poliovirus vaccine and inactivated poliovirus vaccine immunization

Pediatric Infectious Disease, 1991
Although epidemic poliomyelitis in the United States has been eliminated, there are a number of current issues that concern the use of oral attenuated poliovirus vaccine in comparison with the new enhanced-potency inactivated vaccine. Although wild-type poliovirus is almost eradicated in developed nations, vaccine-induced polio exists, at a low but ...
openaire   +3 more sources

Surveillance for Poliovirus Vaccine Adverse Events, 1991 to 1998: Impact of a Sequential Vaccination Schedule of Inactivated Poliovirus Vaccine Followed by Oral Poliovirus Vaccine

Pediatrics, 2001
Background. The elimination of wild-virus–associated poliomyelitis in the Western Hemisphere in 1991 and rapid progress in global polio eradication efforts changed the risk-benefit ratio associated with the exclusive use of oral poliovirus vaccine (OPV) for routine immunization. These changes, plus the November 1987
M. Miles Braun, Robert T. Chen, Wendy A. Wattigney, Gina T. Mootrey   +3 more
openaire   +3 more sources

Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use

The Lancet, 2022
Matilda Hill, A. Bandyopadhyay, A. Pollard   +2 more
semanticscholar   +1 more source